178 related articles for article (PubMed ID: 30628161)
1. Mission-oriented translational cancer research - health economics.
Jönsson B; Sullivan R
Mol Oncol; 2019 Mar; 13(3):636-647. PubMed ID: 30628161
[TBL] [Abstract][Full Text] [Related]
2. Bending the Cost Curve in Childhood Cancer.
Russell H; Bernhardt MB
Curr Hematol Malig Rep; 2016 Aug; 11(4):295-302. PubMed ID: 27193602
[TBL] [Abstract][Full Text] [Related]
3. Burden of illness and research investments in translational sciences for pharmaceuticals in metastatic cancers.
Wang WJ; Robertson JC; Basu A
J Comp Eff Res; 2017 Jan; 6(1):15-24. PubMed ID: 27934549
[TBL] [Abstract][Full Text] [Related]
4. United healthcare, five oncology practices try bundled payments.
Goozner M
J Natl Cancer Inst; 2011 Jan; 103(1):8-10. PubMed ID: 21169535
[No Abstract] [Full Text] [Related]
5. Seeking value as cancer drug costs soar.
Bender E
Cancer Discov; 2013 Aug; 3(8):833-4. PubMed ID: 23928760
[TBL] [Abstract][Full Text] [Related]
6. Health economics of care for patients with cancer and intractable disease in Japan.
Hisashige A; Katayama T; Mikasa H
Support Care Cancer; 1998 Nov; 6(6):503-10. PubMed ID: 9833298
[TBL] [Abstract][Full Text] [Related]
7. Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value.
Serritella AV; Strohbehn GW; Goldstein DA; Lichter AS; Ratain MJ
Clin Pharmacol Ther; 2020 Sep; 108(3):487-493. PubMed ID: 32298471
[TBL] [Abstract][Full Text] [Related]
8. Health policy: Putting a price on cancer.
Sullivan R; Aggarwal A
Nat Rev Clin Oncol; 2016 Mar; 13(3):137-8. PubMed ID: 26856742
[No Abstract] [Full Text] [Related]
9. [Pharmacoeconomics and cost of cancer drugs].
Camps Herrero C; Caballero Díaz C; Blasco Cordellat A
Farm Hosp; 2010 Mar; 34 Suppl 1():12-5. PubMed ID: 20920852
[TBL] [Abstract][Full Text] [Related]
10. Academia and society should join forces to make anti-cancer treatments more affordable.
Berns A
Mol Oncol; 2024 Jun; 18(6):1351-1354. PubMed ID: 38634213
[TBL] [Abstract][Full Text] [Related]
11. Perspectives on Cost and Value in Cancer Care.
Saltz LB
JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
[No Abstract] [Full Text] [Related]
12. The reality of economics for oncologists.
Taylor D
Breast; 2017 Jun; 33():183-190. PubMed ID: 28432979
[TBL] [Abstract][Full Text] [Related]
13. Value-engineered translation for regenerative medicine: meeting the needs of health systems.
Bubela T; McCabe C
Stem Cells Dev; 2013 Dec; 22 Suppl 1(Suppl 1):89-93. PubMed ID: 24304083
[TBL] [Abstract][Full Text] [Related]
14. The economics of cancer care in the UK.
Bosanquet N; Sikora K
Lancet Oncol; 2004 Sep; 5(9):568-74. PubMed ID: 15337487
[TBL] [Abstract][Full Text] [Related]
15. A review of economic impact of targeted oral anticancer medications.
Shen C; Chien CR; Geynisman DM; Smieliauskas F; Shih YC
Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):45-69. PubMed ID: 24378038
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars.
Henry D; Taylor C
Semin Oncol; 2014 Apr; 41 Suppl 3():S13-20. PubMed ID: 24767632
[TBL] [Abstract][Full Text] [Related]
17. Cancer Drugs Fund of minimal benefit.
Burki TK
Lancet Oncol; 2017 Jun; 18(6):e305. PubMed ID: 28483412
[No Abstract] [Full Text] [Related]
18. Charting the Course: Use of Clinical Pathways to Improve Value in Cancer Care.
Malin JL
J Clin Oncol; 2020 Feb; 38(4):367-371. PubMed ID: 31804871
[No Abstract] [Full Text] [Related]
19. Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies.
da Veiga CRP; da Veiga CP; Drummond-Lage AP
Crit Rev Oncol Hematol; 2018 Sep; 129():133-145. PubMed ID: 30097232
[TBL] [Abstract][Full Text] [Related]
20. Why managed care should provide supportive therapies for cancer patients.
Rubenstein SA
Manag Care; 1995 Aug; 4(8):37-9. PubMed ID: 10145013
[No Abstract] [Full Text] [Related]
[Next] [New Search]
